ABSORB III Trial to test the Bioresorbable Vascular Scaffold (BVS)
Purpose
ABSORB III will evaluate the safety and effectiveness of the Absorb Bioresorbable Vascular Scaffold (BVS) System compared to the XIENCE in the treatment of subjects, including those with diabetes mellitus, with coronary artery disease (ischemic heart disease).
Procedures
- Participants will be randomized to receive the Absorb BVS or XIENCE
- Study may last 1-5 years
Eligibility
- Myocardial ischemia (coronary artery disease)
- Candidate for coronary artery bypass graft (CABG) surgery
Contact study coordinator for additional criteria.
Age
18 to 65
65 and over
Gender
Male
Female
Can be done from home
No
Keywords
Coronary Artery Disease, ischemic heart disease, coronary heart disease, Myocardial ischemia, anginaPrincipal Investigator
Theodore Bass, PROF & PRG DIRDepartment
JAX MEDICINE-GENERAL
Contact Information
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.